Abstract
Introduction: Immunocompromised individuals including solid organ transplants recipients present with blunted immune responses to two doses of SARS-CoV-2 mRNA vaccine. Studies have shown that patients with Idiopathic Pulmonary Fibrosis (IPF) present with disrupted cellular and humoral immune response.
Aim and objectives: To investigate immune response following SARS-CoV-2 mRNA vaccine in patients with IPF.
Methods: We compared anti–SARS-CoV-2 antibodies three months after the second dose of the mRNA vaccine BNT162b2 in: 1) patients with IPF receiving antifibrotics, 2) patients with IPF under no treatment, 3) aged-matched controls.
Results: Sixty-seven (n=67) subjects were included in the analysis (patients with IPF receiving antifibrotics: 32, patients with IPF under no treatment: 10, controls: 25). Groups were age and gender balanced. Both groups of patients with IPF whether receiving or not antifibrotic compounds exhibited similarly reduced levels of anti–SARS-CoV-2 antibodies after two doses of the mRNA vaccine BNT162b2 compared to general population [IPF/treatment: 666.1, (95%: 540.1 to 900.0) vs IPF/no treatment: 579.5 (95% CI: 232.4 to 4054.2) vs controls: 2118.6 (95% CI: 1248.3 to 4035.5), p=0.002]. The prevalence of anti–SARS-CoV-2 antibodies above the suggested cut-off threshold of 1000 AU/ml was 21.9%, 40% and 72% in the IPF/treatment, IPF/no treatment and control groups, respectively.
Conclusions: Patients with IPF did not mount appreciable antispike antibody responses to two doses of the mRNA vaccine BNT162b2 compared to general population. National authorities should prioritize patients with IPF for booster doses.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 972.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022